Company
Headquarters: Cambridge, MA, United States
Founded: 2000 in Cambridge, Massachusetts
Employees: 426
CEO: Mr. Gary L. Crocker M.B.A., MBA
$189.8 Million
USD as of Jan. 1, 2024
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $0 |
| EBITDA | $0 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |
Merrimack Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: MACK wb_incandescent
Stock: FSX: MP6N wb_incandescent
Stock: XSTU: MP6N wb_incandescent